Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size, Share, Growth, Opportunities, Global Analysis and Opportunity Assessment 2020 – 2027
![]() |
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market |
ATTR-CM (transthyretin amyloid cardiomyopathy) is a type of amyloidosis that affects the heart, causing heart muscles to stiffen and eventually leading to heart failure. ATTR-CM frequently causes heart failure symptoms such as fatigue, shortness of breath, and peripheral edoema, as well as other symptoms associated with amyloid fibril buildup in the body. Transthyretin amyloid cardiomyopathy (ATTR-CM) is classified into two types: hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis (wATTR) (wtATTR). This disease is frequently diagnosed only after the symptoms have progressed to a severe level.
Ongoing R&D activities are expected to propel the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market forward. Major market players are concentrating their efforts on the research and development of transthyretin amyloid cardiomyopathy (ATTR-CM) treatments, which are expected to drive market growth during the forecast period. In January 2020, Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. launched the CARDIO-TTRansform Phase III cardiovascular outcomes study for AKCEA-TTR-LRx in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
The failure to diagnose transthyretin amyloid cardiomyopathy (ATTR-CM) is expected to stymie market growth. According to the Amyloidosis Foundation, among the two types of transthyretin amyloid cardiomyopathy (ATTR-CM), wild type transthyretin amyloidosis (wtATTR) is more difficult to diagnose than hereditary transthyretin amyloidosis (hATTR) because there is no family history or genetic marker for the disease.
Market Segmentation:
By Type
- Hereditary Transthyretin Amyloidosis (hATTR)
- Wild Type Transthyretin Amyloidosis (wtATTR)
By Drug Type
- Transthyretin Stabilizers
- Nonsteroidal anti-inflammatory drugs (NSAID)
- RNAi therapy
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Comments
Post a Comment